Related Experiment Video
Updated: Nov 26, 2025
08:09
Vessel-sparing Excision and Primary Anastomosis
Published on: January 7, 2019
11.8K
Prostatic Artery Embolization in Refractory Hematuria of Prostatic Origin
Issam Kably1, Vedant Acharya2, Andrew J Richardson3
1Department of Interventional Radiology, University of Miami Miller School of Medicine, Miami, FL.
Techniques in Vascular and Interventional Radiology
|December 14, 2020
Summary
Refractory hematuria from benign prostatic hyperplasia (BPH) can be treated with prostate artery embolization (PAE). This minimally invasive procedure offers an alternative to traditional treatments for persistent prostatic bleeding.
Area of Science:
- Urology
- Interventional Radiology
Background:
- Hematuria of prostatic origin stems from various causes, including benign prostatic hyperplasia (BPH), trauma, cancer, and radiation.
- BPH-related hematuria can arise from gland vascularity or post-surgical regrowth.
- Refractory cases may necessitate hospitalization and aggressive interventions like transfusions and continuous bladder irrigation.
Purpose of the Study:
- To review the current evidence on prostate artery embolization (PAE) for treating refractory hematuria of prostatic origin.
- To highlight PAE as an emerging minimally invasive option for BPH-related bleeding.
Main Methods:
- Literature review of studies investigating prostate artery embolization for prostatic hematuria.
- Analysis of evidence regarding PAE's efficacy and safety in managing refractory bleeding.
Main Results:
- Prostate artery embolization was initially developed for refractory prostatic hematuria.
- PAE is an emerging minimally invasive therapy for men with BPH and persistent bleeding.
Conclusions:
- Prostate artery embolization is a viable treatment option for refractory hematuria of prostatic origin.
- Evidence supports PAE as a minimally invasive therapeutic approach for BPH-related bleeding.
Related Concept Videos
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
290
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
290
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
330
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
330